Menu
Enrolling by invitation NCT07154238

Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.

— Observational Obesity

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: No treatment given.
Who it may be relevant to
Registry conditions: Obesity. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Germany
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The purpose of this study is to collect information for scientific research and to better understand the experiences of participants managing their weight. The study aims to collect valid responses through online interviews from participants. This study is a survey-based study without collection of laboratory data. Duration of the study will be about 14 months.

Interventions

  • Other No treatment given
    No treatment given

Primary outcome measures

  • Description of characteristics, including clinical, demographic and physical characteristics, among individuals initiated on injectable semaglutide for weight management [Time frame: At the time of survey response (Day 1)]
  • Description of the experience of individuals initiated on injectable semaglutide for weight management through personal perception of physical and mental health and self-reported QoL [Time frame: At the time of survey response (Day 1)]
  • Individual-reported change in BMI since initiation [Time frame: At the time of survey response (Day 1)]
  • Individual-reported achievement of weight loss goal [Time frame: At the time of survey response (Day 1)]
  • Individual-reported change in weight since initiation [Time frame: At the time of survey response (Day 1)]
  • Individual-reported changes in daily life since initiation on injectable semaglutide [Time frame: At the time of survey response (Day 1)]
Secondary outcome measures (12)
  • Treatment expectation of individuals initiated on injectable semaglutide of ability to achieve weight loss goal using injectable semaglutide [Time frame: At the time of survey response (Day 1)]
  • Expectation for length of time of treatment to desired result from date of initiation on injectable semaglutide at baseline [Time frame: At the time of survey response (Day 1)]
  • Expectation of individuals initiated on injectable semaglutide for weight management who believe they will have greater success in achieving their weight loss with the use of injectable semaglutide [Time frame: At the time of survey response (Day 1)]
  • Expected benefits of injectable semaglutide [Time frame: At the time of survey response (Day 1)]
  • Satisfaction with weight loss since initiation [Time frame: At the time of survey response (Day 1)]
  • Overall satisfaction with injectable semaglutide [Time frame: At the time of survey response (Day 1)]
  • Individual-reported changes in perception of injectable semaglutide since initiation [Time frame: At the time of survey response (Day 1)]
  • Attitudes of individuals related to obesity or weight related stigmatization or discrimination prior to/since/due to initiation on injectable semaglutide [Time frame: At the time of survey response (Day 1)]
  • Attitudes of individuals initiated on injectable semaglutide for weight management related to obesity as a chronic disease [Time frame: At the time of survey response (Day 1)]
  • Attitudes of individuals initiated on injectable semaglutide for weight management related to weight loss being their responsibility [Time frame: At the time of survey response (Day 1)]
  • Attitudes of individuals initiated on injectable semaglutide for weight management related to weight loss being more likely with use of prescription medication for weight loss (AOMs) [Time frame: At the time of survey response (Day 1)]
  • Degree of knowledge of individuals initiated on injectable semaglutide for weight management related to how prescription weight loss medications (AOMs) work in the body [Time frame: At the time of survey response (Day 1)]

Eligibility criteria

Inclusion criteria

  • For an eligible participant (individuals initiated on injectable semaglutide for weight management), all inclusion criteria must be answered "yes".
  • Electronically provided consent obtained before any study-related activities can be completed.
  • Age above or equal to 18 years at the time of providing informed consent.
  • Reside in a participating country: Australia, Germany, United Arab Emirates (UAE) and Spain.
  • Have been prescribed and initiated injectable semaglutide for weight management prior to study screening.
  • For an eligible participant (HCPs), all inclusion criteria must be answered "yes".
  • Electronically provided consent obtained before any study-related activities can be completed.
  • Practice in a participating country: Australia, Germany, UAE, and Spain.
  • See at least 150 patients for any condition per month; priority given to those who treat at least 200 patients for any condition per month.
  • Treat at least 10 adult patients per month for weight management.
  • Prescribe anti-obesity medications (AOMs) to their patients they personally treat for weight management/obesity care; priority given to those who treat at least 10% of the patients they personally treat for weight management/obesity care with anti-obesity medications (AOMs).
  • Prescribe injectable semaglutide for weight management.
  • Be a specialty of interest (varies by country); mix of primary care, specialists such as Endocrinologists, Diabetologists, Nutrition Specialists, Obesity Specialists and others.

Exclusion criteria

  • For an eligible participant (individuals initiated on injectable semaglutide for weight management), all exclusion criteria must be answered "no".
  • Unwillingness or language barriers precluding adequate understanding or cooperation.
  • Is currently or planning to become pregnant in next six months.
  • Is taking injectable semaglutide for Type 2 diabetes management only.
  • For an eligible participant (HCPs), all exclusion criteria must be answered "no".
  • Prior participation in this study. Participation is defined as having given informed consent and submitting responses to an interview.
  • Unwillingness or language barriers precluding adequate understanding or cooperation.
  • Only treats patients under 18 years of age.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-only

Study locations

Germany · 1 center
  • Novo Nordisk Investigational Site — Bad Oeynhausen

Identifiers

NCT: NCT07154238 · NN9536-8412 · U1111-1314-6149

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗